04:00 , Jan 4, 2019 |  BC Week In Review  |  Financial News

Suzhou Connect raises $55M series B, plans Phase Ib of dermatitis candidate

Suzhou Connect Biopharmaceuticals Ltd. (Taicang, China) raised $55 million on Jan. 2 in a series B round led by new investor Advantech Capital and announced plans to start a Phase Ib trial this quarter of...
01:06 , Jan 3, 2019 |  BC Extra  |  Financial News

Suzhou Connect raises $55M series B, plans Phase Ib of dermatitis candidate

Suzhou Connect Biopharmaceuticals Ltd. (Taicang, China) raised $55 million in a series B round Wednesday led by new investor Advantech Capital and announced plans to start a Phase Ib trial this quarter of its second...
22:08 , May 3, 2017 |  BC Extra  |  Company News

Pieris, AZ in respiratory deal for Anticalins

Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) climbed $1.27 (53%) to $3.67 after it said it partnered with AstraZeneca plc (LSE:AZN; NYSE:AZN) to advance up to five respiratory disease candidates developed using the biotech's Anticalin platform, including one...
16:04 , Apr 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest antagonizing CD124 or promoting DUSP4 expression could help treat breast cancer. In patients, low levels of the DUSP4 negative regulator IL-4 , and high...
00:53 , Jan 26, 2017 |  BC Extra  |  Financial News

Connect raises $20M series A round

Connect Biopharmaceuticals Ltd. (Suzhou, China) said it raised $20 million in an oversubscribed series A round led by Qiming Venture Partners. Also participating were Northern Light Venture Capital, Lapan Capital and Cowin Venture Capital. The...